Health AI Central
Share:
Peer-Reviewed Publication
Schizophr Res2025;27542-51.January 1, 2025Journal Article

AI-based medication adherence prediction in patients with schizophrenia and attenuated psychotic disorders.

Zheng Zhu1, Dooti Roy2, Shaolei Feng3, Brian Vogler4
1Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA. Electronic address: zheng.zhu@boehringer-ingelheim.com.
2Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA. Electronic address: dooti.roy@boehringer-ingelheim.com.
3AiCure, LLC, 214 Sullivan Street, New York, NY 10012, USA. Electronic address: shaolei.feng@aicure.com.
4Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA. Electronic address: brian.vogler@boehringer-ingelheim.com.
PubMed DOI

Abstract

OBJECTIVE: The capacity of machine-learning algorithms to predict medication adherence was assessed using data from AiCure, a computer vision-assisted smartphone application, which records the medication ingestion event. METHODS: Patients treated with BI 409306 were recruited from two Phase II randomized, placebo-controlled trials in schizophrenia (NCT03351244) and attenuated psychotic disorders…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.